These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
35 related articles for article (PubMed ID: 6619578)
1. Efficacy and tolerance of intranasally applied recombinant leukocyte A interferon in normal volunteers. Samo TC; Greenberg SB; Couch RB; Quarles J; Johnson PE; Hook S; Harmon MW J Infect Dis; 1983 Sep; 148(3):535-42. PubMed ID: 6619578 [TBL] [Abstract][Full Text] [Related]
2. Interferon-based agents for current and future viral respiratory infections: A scoping literature review of human studies. Mesic A; Jackson EK; Lalika M; Koelle DM; Patel RC PLOS Glob Public Health; 2022; 2(4):e0000231. PubMed ID: 36962150 [TBL] [Abstract][Full Text] [Related]
3. Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds. Radanovic I; Klarenbeek N; Rissmann R; Groeneveld GJ; van Brummelen EMJ; Moerland M; Bosch JJ Front Oncol; 2022; 12():954806. PubMed ID: 36106110 [TBL] [Abstract][Full Text] [Related]
4. Antiviral potential of human IFN-α subtypes against influenza A H3N2 infection in human lung explants reveals subtype-specific activities. Matos ADR; Wunderlich K; Schloer S; Schughart K; Geffers R; Seders M; Witt M; Christersson A; Wiewrodt R; Wiebe K; Barth P; Hocke A; Hippenstiel S; Hönzke K; Dittmer U; Sutter K; Rescher U; Rodionycheva S; Matera N; Ludwig S; Brunotte L Emerg Microbes Infect; 2019; 8(1):1763-1776. PubMed ID: 31826721 [TBL] [Abstract][Full Text] [Related]
5. Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead. Velkov T; Abdul Rahim N; Zhou QT; Chan HK; Li J Adv Drug Deliv Rev; 2015 May; 85():65-82. PubMed ID: 25446140 [TBL] [Abstract][Full Text] [Related]
6. The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery. Rollinger JM; Schmidtke M Med Res Rev; 2011 Jan; 31(1):42-92. PubMed ID: 19714577 [TBL] [Abstract][Full Text] [Related]
7. Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Couch RB; Atmar RL; Cate TR; Quarles JM; Keitel WA; Arden NH; Wells J; Niño D; Wyde PR Vaccine; 2009 Aug; 27(39):5344-8. PubMed ID: 19607949 [TBL] [Abstract][Full Text] [Related]
8. Antimicrobial strategies: an option to treat allergy? Papadopoulos NG; Konstantinou GN Biomed Pharmacother; 2007 Jan; 61(1):21-8. PubMed ID: 17188832 [TBL] [Abstract][Full Text] [Related]
9. New treatment regimes for virus-induced exacerbations of asthma. Edwards MR; Kebadze T; Johnson MW; Johnston SL Pulm Pharmacol Ther; 2006; 19(5):320-34. PubMed ID: 16289761 [TBL] [Abstract][Full Text] [Related]
15. The interferon system as a basis for antiviral therapy or prophylaxis. Billiau A Antiviral Res; 1985; Suppl 1():131-40. PubMed ID: 3936410 [No Abstract] [Full Text] [Related]
17. The need for new antiviral agents. Freestone DS Antiviral Res; 1985 Dec; 5(6):307-24. PubMed ID: 3004326 [TBL] [Abstract][Full Text] [Related]
18. Demonstration of dose-response relationship in seasonal prophylaxis of respiratory infections with alpha-2b interferon. Monto AS; Albrecht JK; Schwartz SA Antimicrob Agents Chemother; 1988 Jan; 32(1):47-50. PubMed ID: 2831814 [TBL] [Abstract][Full Text] [Related]
19. Ineffectiveness of postexposure prophylaxis of rhinovirus infection with low-dose intranasal alpha 2b interferon in families. Monto AS; Schwartz SA; Albrecht JK Antimicrob Agents Chemother; 1989 Mar; 33(3):387-90. PubMed ID: 2543280 [TBL] [Abstract][Full Text] [Related]